Rani Therapeutics Holdings (RANI) Stock Analysis & Winston Score

Rani Therapeutics is a small biotech company working on a technology that turns injectable drugs into pills. Instead of getting a shot, patients could swallow a capsule that delivers the medicine inside the intestine using tiny needles. The company is focused on making it easier to take biological drugs — medicines that today must be injected — and its main customers would be patients and pharmaceutical partners who license the technology. Rani makes money primarily through research partnerships and licensing deals with larger drug companies, not from selling approved products yet. It is a clinical-stage company based in the United States, meaning it has no approved drugs on the market and is still spending heavily on research and trials, which explains the deeply negative operating margin. The key growth driver is successfully advancing its RaniPill platform through clinical trials and securing partnerships, but the main risk is that it could run out of funding before any product reaches approval.